axicabtagene ciloleucel
Gilead,Daiichi Sankyo
['lymsm']
 i agree it s a super important study but the toxicity was more than i expected, what was your impression? i also wish presenters would formally define their safety/tolerability thresholds especially for single-arm phase 2 studies. #ash22 #lymsm
Oncology fellow @SitemanCenter @WUHemeOncFellow @WUSTLmed | lymphoma/leukemia researcher @LabFehniger | all views 100% my own